Provider: Silverchair
Database: AmericanMedicalAssociation
Content: text/plain; charset="UTF-8"

TY  - JOUR
AU  - Greene, Stephen J.
AU  - Butler, Javed
AU  - Fonarow, Gregg C.
T1  - Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed
PY  - 2021
Y1  - 2021/07/01
DO  - 10.1001/jamacardio.2021.0496
JO  - JAMA Cardiology
JA  - JAMA Cardiol
VL  - 6
IS  - 7
SP  - 743
EP  - 744
SN  - 2380-6583
AB  - Many eligible patients with heart failure (HF) with reduced ejection fraction (HFrEF) never receive therapies shown to extend survival or receive them with much delay. Multiple recent successes in pharmacotherapy for HFrEF provide impetus for embracing change in HFrEF treatment in clinical practice. Quadruple therapy with an angiotensin receptor–neprilsyin inhibitor (ARNI), evidence-based β-blocker, mineralocorticoid receptor antagonist (MRA), and sodium glucose cotransporter 2 inhibitor (SGLT2i) may reduce risk of death by 73% over 2 years. Herein, we present the case for simultaneous or rapid sequence initiation of these 4 lifesaving therapies (Figure).
Y2  - 5/20/2024
UR  - https://doi.org/10.1001/jamacardio.2021.0496
ER  -